NDLI: Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls

Content Provider	Springer Nature : BioMed Central
Author	Kvartsberg, Hlin Portelius, Erik Andreasson, Ulf Brinkmalm, Gunnar Hellwig, Konstantin Lelental, Natalia Kornhuber, Johannes Hansson, Oskar Minthon, Lennart Spitzer, Philipp Maler, Juan M Zetterberg, Henrik Blennow, Kaj Lewczuk, Piotr
Abstract	Introduction Synaptic dysfunction and degeneration are central events in Alzheimer’s disease (AD) pathophysiology that are thought to occur early in disease progression. Synaptic pathology may be studied by examining protein biomarkers specific for different synaptic elements. We recently showed that the dendritic protein neurogranin (Ng), including the endogenous Ng peptide 48 to 76 (Ng48–76), is markedly increased in cerebrospinal fluid (CSF) in AD and that Ng48–76 is the dominant peptide in human brain tissue. The aim of this study was to characterize Ng in plasma and CSF using mass spectrometry and to investigate the performance of plasma Ng as an AD biomarker. Methods Paired plasma and CSF samples from patients with AD (n = 25) and healthy controls (n = 20) were analyzed in parallel using an immunoassay developed in-house on the Meso Scale Discovery platform and hybrid immunoaffinity-mass spectrometry (HI-MS). A second plasma material from patients with AD (n = 13) and healthy controls (n = 17) was also analyzed with HI-MS. High-resolution mass spectrometry was used for identification of endogenous plasma Ng peptides. Results Ng in human plasma is present as several endogenous peptides. Of the 16 endogenous Ng peptides identified, seven were unique for plasma and not detectable in CSF. However, Ng48–76 was not present in plasma. CSF Ng was significantly increased in AD compared with controls (P < 0.0001), whereas the plasma Ng levels were similar between the groups in both studies. Plasma and CSF Ng levels showed no correlation. CSF Ng was stable during storage at −20°C for up to 2 days, and no de novo generation of peptides were detected. Conclusions For the first time, to our knowledge, we have identified several endogenous Ng peptides in human plasma. In agreement with previous studies, we show that CSF Ng is significantly increased in AD as compared with healthy controls. The origin of Ng in plasma and its possible use as a biomarker need to be further investigated. The results suggest that CSF Ng, in particular Ng48–76, might reflect the neurodegenerative processes within the brain, indicating a role for Ng as a potential novel clinical biomarker for synaptic function in AD.
Related Links	https://alzres.biomedcentral.com/counter/pdf/10.1186/s13195-015-0124-3.pdf
Ending Page	9
Page Count	9
Starting Page	1
File Format	HTM / HTML
ISSN	17589193
DOI	10.1186/s13195-015-0124-3
Journal	Alzheimer's Research & Therapy
Issue Number	1
Volume Number	7
Language	English
Publisher	BioMed Central
Publisher Date	2015-07-01
Access Restriction	Open
Subject Keyword	Neurosciences Neurology Geriatrics Gerontology Geriatric Psychiatry Endogenous Peptide Meso Scale Discovery Paired Plasma Acclaim PepMap Paired Cohort Geriatrics/Gerontology
Content Type	Text
Resource Type	Article
Subject	Neurology Neurology (clinical) Cognitive Neuroscience
Journal Impact Factor	8/2023
5-Year Journal Impact Factor	8.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum

Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample

Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology

Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls

Similar Documents

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum

Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample

Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology

Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls